Showing results (101-110 of 135) with videos related to

Sort By:
Pageof 14
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Mitochondrial Imaging Detects Early Cardiac Responses to Cancer ImmunotherapyHee-Don Chae, Uttam Shrestha, Millie Das, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Molecular Imaging and Biology|September 4, 2020
Safety and Stability of Antibody-Dye Conjugate in Optical Molecular ImagingJacqueline Pei, Georgina Juniper, Nynke S van den Berg, et al.
The Journal of Clinical Investigation|May 20, 2014
Targeting CD137 enhances the efficacy of cetuximabHolbrook E Kohrt, A Dimitrios Colevas, Roch Houot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2022
89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell CarcinomaYu-Jin Lee, Nynke S van den Berg, Heying Duan, et al.
JACC. Cardiooncology|August 14, 2025
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving ImmunotherapyEvaline Cheng, Maja Ivanovic, Antonia Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer ImmunotherapyHee-Don Chae, Uttam Shrestha, Millie Das, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Pageof 14